RTSN — Retension Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $127.06m
- $141.74m
Annual balance sheet for Retension Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Cash and Short Term Investments | 8.19 | 18.9 |
| Prepaid Expenses | ||
| Total Current Assets | 8.37 | 21.4 |
| Total Assets | 8.37 | 21.4 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 0.277 | 0.912 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Liabilities | 0.277 | 0.912 |
| Non Redeemable Preferred Stock | ||
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Total Equity | 8.09 | 20.5 |
| Total Liabilities & Shareholders' Equity | 8.37 | 21.4 |
| Total Common Shares Outstanding |